Bristol Myers secures FDA label expansion for anemia drug Reblozyl
Bristol Myers Squibb has scored another win for its anemia drug Reblozyl, revealing Monday evening the FDA granted the drug its third indication.
The FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
